Is Oncothyreon Inc (USA) (NASDAQ:ONTY) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. It’s not surprising given that hedge funds have access to better information and more resources to find the latest market-moving information.
Oncothyreon Inc (USA) (NASDAQ:ONTY) has seen an increase in activity from the world’s largest hedge funds in recent months. ONTY was in 19 hedge funds’ portfolios at the end of September. There were 18 hedge funds in our database with ONTY holdings at the end of the previous quarter. At the end of this article we will also compare ONTY to other stocks, including Nam Tai Property Inc (NYSE:NTP), Ignyta Inc (NASDAQ:RXDX), and Hovnanian Enterprises, Inc. (NYSE:HOV) to get a better sense of its popularity.
Follow Cascadian Therapeutics Inc. (NASDAQ:CASC)
Follow Cascadian Therapeutics Inc. (NASDAQ:CASC)
To most stock holders, hedge funds are assumed to be underperforming, outdated financial vehicles of years past. While there are greater than an 8000 funds in operation at present, Our researchers hone in on the elite of this club, around 700 funds. These investment experts administer the lion’s share of all hedge funds’ total asset base, and by tracking their first-class investments, Insider Monkey has found various investment strategies that have historically exceeded the market. Insider Monkey’s small-cap hedge fund strategy exceeded the S&P 500 index by 12 percentage points per year for a decade in their back tests.
Keeping this in mind, let’s take a gander at the latest action surrounding Oncothyreon Inc (USA) (NASDAQ:ONTY).
How are hedge funds trading Oncothyreon Inc (USA) (NASDAQ:ONTY)?
Heading into Q4, a total of 19 of the hedge funds tracked by Insider Monkey were long this stock, a change of 6% from one quarter earlier. With hedgies’ sentiment swirling, there exists a select group of noteworthy hedge fund managers who were increasing their stakes significantly (or already accumulated large positions).
According to Insider Monkey’s hedge fund database, Mark Lampert’s Biotechnology Value Fund / BVF Inc has the number one position in Oncothyreon Inc (USA) (NASDAQ:ONTY), worth close to $44.8 million, comprising 9.1% of its total 13F portfolio. The second largest stake is held by venBio Select Advisor, managed by Behzad Aghazadeh, which holds a $15.1 million position; 3.9% of its 13F portfolio is allocated to the stock. Remaining peers that are bullish include Jeremy Green’s Redmile Group, Howard Guberman’s Gruss Asset Management and Oleg Nodelman’s EcoR1 Capital.
